<DOC>
	<DOCNO>NCT01940172</DOCNO>
	<brief_summary>This dose escalation study female subject relapse ovarian cancer ( include epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer ) . Approximately 30 40 subject administer combination conatumumab birinapant . In initial dose-escalation stage study , adult female subject receive conatumumab combination increase dos birinapant dose-escalation cohort determine MTD birinapant administer fix dose conatumumab . In safety expansion stage , adult female subject receive conatumumab combination birinapant MTD combination .</brief_summary>
	<brief_title>Study Birinapant Combination With Conatumumab Subjects With Relapsed Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion CriteriaIf subject : Is woman least 18 year age . Has negative serum pregnancy test screen woman childbearing potential . Pathologically confirm ovarian cancer ( epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer ) may maximum 3 prior systemic chemotherapy regimen ( exclude hormonal therapy investigational agent ) . Has performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Has measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion AND meet Gynecologic Cancer InterGroup ( GCIG ) CA 125 criterion . Has life expectancy least 3 month . Has adequate liver , renal , pancreatic , coagulation bone marrow function . Exclusion CriteriaIf subject : Has symptomatic uncontrolled brain metastasis require current treatment ( &lt; 8 week last cranial radiation treatment &lt; 4 week last steroid treatment ) . Has know intolerance study drug excipients . Has know suspect diagnosis human immunodeficiency virus ( HIV ) chronic active Hepatitis B C. Has uncontrolled hypertension define blood pressure &gt; 160/100 mmHg without medication , control despite medication . Has receive systemic chemotherapy , hormonal therapy , immunotherapy , antitumor necrosis factor ( TNF ) therapy , experimental approve anticancer proteins/antibodies therapy ≤28 day enrollment . Has impair cardiac function clinically significant cardiac disease include follow : 1 . New York Heart Association Grade III IV congestive heart failure . 2 . Myocardial infarction within last 12 month prior dose birinapant . Has QT interval correct heart rate ( QTcB ) &gt; 480 msec ( include subject medication ) . Subjects ventricular pacemaker QT interval measurable may eligible . Has lack recovery prior adverse nonhematological event Grade ≤1 severity ( National Cancer Institute Common Terminology Criteria Adverse Events [ NCI CTCAE ] v4.03 ) ( except alopecia ) due therapy administer prior initiation study drug dosing . Has concurrent disease and/or medical condition , opinion Investigator , would prevent subject 's participation , render subject excessive risk ( include excessive risk due toxicity profile plan combination chemotherapeutic regimen ) , limit subject 's compliance protocol 's required evaluation . Has prior history cranial nerve palsy . Has autoimmune disease inflammatory disease , example , active rheumatoid arthritis , active inflammatory bowel disease chronic inflammatory condition . Has pseudomyxoma , mesothelioma , unknown primary tumor , sarcoma , neuroendocrine histology , clear cell mucinous histology subject borderline ovarian cancer . Requires concomitant chronic use antiTNF therapy , corticosteroid nonsteroidal anti inflammatory drug ( NSAIDS ) . Intermittent use ( 7 few day per 14 day ) corticosteroids premedications allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>